Neurocrine Biosciences
NBIX
$114.38
Share price
-0.37%
Change (1 day)
21.60%
Change (1 year)
Categories
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.
Neurocrine Biosciences (NBIX) - P/B ratio
P/B ratio as of September 2023 : 6.03
According to Neurocrine Biosciences
's latest financial reports the company has a price-to-book ratio of 6.03.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Neurocrine Biosciences - P/B ratio (from 2001 to 2022)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2022-12-31 | 6.72 | 14.33% |
| 2021-12-31 | 5.88 | -26.05% |
| 2020-12-31 | 7.95 | -48.94% |
| 2019-12-31 | 15.6 | 15.47% |
| 2018-12-31 | 13.5 | -26.91% |
| 2017-12-31 | 18.5 | 72.81% |
| 2016-12-31 | 10.7 | -7.13% |
| 2015-12-31 | 11.5 | 40.46% |
| 2014-12-31 | 8.19 | 56.68% |
| 2013-12-31 | 5.22 | 62.26% |
| 2012-12-31 | 3.22 | -58.81% |
| 2011-12-31 | 7.82 | -63.93% |
| 2010-12-31 | 21.7 | -28.38% |
| 2009-12-31 | 30.3 | 801% |
| 2008-12-31 | 3.36 | 129.43% |
| 2007-12-31 | 1.46 | 16.64% |
| 2006-12-31 | 1.26 | -78.98% |
| 2005-12-31 | 5.97 | 30.56% |
| 2004-12-31 | 4.57 | -7.13% |
| 2003-12-31 | 4.92 | -21.13% |
| 2002-12-31 | 6.24 |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 1.88 | -68.89% | 🇺🇸 USA |
 AbbVie ABBV | 20.4 | 238.12% | 🇺🇸 USA |
 Eli Lilly LLY | 48.5 | 704.63% | 🇺🇸 USA |
 Repligen
RGEN | 4.77 | -20.88% | 🇺🇸 USA |
 Athersys ATHX | -0.3070 | -105.09% | 🇺🇸 USA |
 ANI Pharmaceuticals ANIP | 2.83 | -53.13% | 🇺🇸 USA |
 Palatin Technologies PTN | 1.91 | -68.31% | 🇺🇸 USA |
 Royalty Pharma RPRX | 1.26 | -79.17% | 🇬🇧 UK |